相关临床试验
240
45 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1965
进行中（未招募）
41
17.1%
已完成
96
40.0%
Enrolling By Invitation
1
0.4%
尚未招募
3
1.3%
招募中
29
12.1%
终止
16
6.7%
Unknown
52
21.7%
撤回
2
0.8%
暂无批准数据
- A multicenter phase 3 trial of 820 adults showed that full-spectrum cannabis extract VER-01 achieved a significant 1.9-point reduction in pain intensity compared to 1.4 points with placebo over 12 weeks. - The study found 54.1% of patients receiving VER-01 achieved at least 30% pain reduction versus 39.5% in the placebo group, with particularly strong efficacy in neuropathic pain cases. - The cannabis extract demonstrated a favorable safety profile with no signs of drug dependence or withdrawal, offering a potential non-addictive alternative to opioids for chronic low back pain management. - Results published in Nature Medicine suggest VER-01 could address critical treatment gaps in chronic low back pain, the leading global cause of disability.
- Vertanical's experimental cannabis medication demonstrated statistically significant pain reduction in an 800-patient study, with participants reporting nearly 2-point improvement on an 11-point pain scale compared to 1.4 points for placebo. - The pharmaceutical-grade cannabis extract contains low-dose THC and showed no signs of drug abuse, dependence, or withdrawal among trial participants over 12 weeks. - Results published in Nature journal support cannabis as a potential alternative to opioids for chronic lower back pain, addressing a major unmet medical need affecting millions of patients. - Side effects including dizziness, headache, fatigue and nausea led to 17% discontinuation rate, which researchers noted was lower than typically reported with opioid treatments.
- The DIGIT-HF trial demonstrated that digitoxin significantly reduced the composite risk of all-cause death or hospitalization for worsening heart failure by 18% compared to placebo in patients with heart failure with reduced ejection fraction. - The study enrolled 1,212 patients with advanced heart failure symptoms who were already receiving optimal guideline-directed medical therapy, with 95% on beta-blockers and over 90% on renin-angiotensin system blockers. - Digitoxin showed particular benefit in patients with heart rates ≥75 bpm or systolic blood pressure ≤120 mmHg, while maintaining an acceptable safety profile with serious adverse events occurring in 4.7% of treated patients. - The findings suggest digitoxin may serve as an additional therapeutic option for heart failure patients, especially those with atrial fibrillation, higher heart rates, low blood pressure, or impaired kidney function.
- Preclinical study by Hannover Medical School shows Viromed's cold plasma technology could prevent up to 6,000 deaths per year in Germany from ventilator-associated pneumonia. - The PulmoPlas® device demonstrates significant antimicrobial efficacy without damaging lung tissue, potentially saving two to three lives for every 100 VAP patients treated early. - Viromed plans to apply for special "fast-track" approval in late summer 2025, targeting a critical gap in intensive care medicine where up to 40% of ventilated patients develop VAP with mortality rates reaching 50%.
- Viromed Medical AG is advancing research on cold plasma technology as a potential "digital antibiotic" for preventing ventilator-associated pneumonia (VAP), which affects 23-36% of mechanically ventilated patients in Germany with a mortality rate of 10-13%. - The study is led by Prof. Dr. Hortense Slevogt of the BREATH research network at Hannover Medical School, investigating the safety and efficacy of cold plasma to kill respiratory bacteria without developing antibiotic resistance. - Cold plasma technology offers rapid action against antibiotic-resistant pathogens by physically destroying germs within minutes, potentially revolutionizing treatment for ventilated patients and reducing healthcare system burden. - With approximately 486,000 patients requiring mechanical ventilation in German ICUs in 2023, the technology could address a significant unmet medical need in critical care medicine.
